Sellem, B.; Abdi, B.; Lê, M.; Tubiana, R.; Valantin, M.-A.; Seang, S.; Schneider, L.; Fayçal, A.; Peytavin, G.; Soulié, C.;
et al. Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV. J. Pers. Med. 2023, 13, 583.
https://doi.org/10.3390/jpm13040583
AMA Style
Sellem B, Abdi B, Lê M, Tubiana R, Valantin M-A, Seang S, Schneider L, Fayçal A, Peytavin G, Soulié C,
et al. Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV. Journal of Personalized Medicine. 2023; 13(4):583.
https://doi.org/10.3390/jpm13040583
Chicago/Turabian Style
Sellem, Baptiste, Basma Abdi, Minh Lê, Roland Tubiana, Marc-Antoine Valantin, Sophie Seang, Luminita Schneider, Antoine Fayçal, Gilles Peytavin, Cathia Soulié,
and et al. 2023. "Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV" Journal of Personalized Medicine 13, no. 4: 583.
https://doi.org/10.3390/jpm13040583
APA Style
Sellem, B., Abdi, B., Lê, M., Tubiana, R., Valantin, M.-A., Seang, S., Schneider, L., Fayçal, A., Peytavin, G., Soulié, C., Marcelin, A.-G., Katlama, C., Pourcher, V., & Palich, R.
(2023). Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV. Journal of Personalized Medicine, 13(4), 583.
https://doi.org/10.3390/jpm13040583
